BIOPHAGE PHARMA (fka BIPMF)

[oasdihf]

Biophage Pharma initiates performance and validation testing of PDS96(R) Biosensor

10:59 EST Wednesday, December 06, 2006

Important milestone reached in the development of new biosensor

MONTREAL, Dec. 6 /CNW Telbec/ - (TSX.V: BUG) - Biophage Pharma Inc. reported today that it has reached an important milestone in the development of a compact PDS96(R) Biosensor. The company is now conducting extensive in-house performance testing and validation of the alpha prototype, and expects to file US and PCT patents in the first quarter of 2007.

The Biosensor's compact size, performance and functionality promise to be a quantum leap over existing technologies. Moreover, it uses specially designed sample arrays in a standard 96 well plate configuration, making it amenable to high throughput automation. Data acquisition and analysis are handled with user-friendly software.

"The increased capacity, functions and lower selling price of the PDS96(R) Biosensor will result in substantial savings of time, money and human resources for our customers. These features give us an important edge over our competitors and responds to true concerns of consumers in the health care industry," commented Dr Rosemonde Mandeville, President and CEO of Biophage Pharma Inc.

"Our market assessment has confirmed that a compact biosensor that can screen large number of samples for bacterial sterility and toxicity testing has important applications for cosmetic or pharmaceutical products, as well as in blood banks, laboratories, hospitals, and even teaching centers," added Dr. Mandeville.

"Biophage is in a better position than it has ever been. We believe we have a unique device that offers superior technology, throughput and cost advantages over our competitors who are many times our size," concluded Dr. Mandeville.

About Biophage Pharma Inc.

Biophage Pharma is a high potential, revenue-driven Canadian biotechnology company focused on the development of innovative phage-based products and technologies for the detection and management of bacterial contaminations. Founded in 1995, Biophage operates three divisions: (1) The Therapeutic division for the management of bacterial contaminations in the medical, veterinary and environmental fields; (2) The Biosensors division for the development and commercialization of new diagnostic products, more particularly a compact PDS96(R) Biosensor which is entering in the pre-commercialization stage; (3) The Immunotox Labs division, which provides services in Immunogenicity and Immunotoxicity, Nanotoxicity and Ecotoxicology, Beryllium sensitivity testing and MELISA(R) testing for the detection of sensitization to more than 200 different allergens including metals, penicillin, gluten and pollens.

(www.biophagepharma.net ; www.immunotoxlabs.com).


<<
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
>>
%SEDAR: 00014714EF

For further information: Biophage Pharma Inc.: Rosemonde Mandeville, M.B., Ch.B., PhD. President and Chief Executive Officer, [phone], [e-mail]; Renmark Financial Communications Inc.: Christine Stewart: [e-mail]: Ricardo Vallejos: [e-mail], [phone], Fax : [phone], www.renmarkfinancial.com